Menlo Security Joins VMware SD-WAN Security Technology Partner Program to Deliver Secure Cloud Transformation
6.11.2019 11:00:00 EET | Business Wire | Press release
Menlo Security, a leader in cloud security, today announced a new integration with VMware SD-WAN by VeloCloud, which offers the industry’s most flexible enterprise SD-WAN architecture. The solution delivers Secure Cloud Transformation, which optimizes and secures local Internet breakouts and enables global low latency access to the Internet and business-critical SaaS applications for an enterprise’s entire local and remote workforce. The integration is available immediately to all VMware SD-WAN customers.
“Menlo Security helps some of the largest enterprises and government agencies in the world transform their infrastructure and move security to the cloud, while maintaining global visibility and control of their traffic,” said Poornima DeBolle, chief product officer at Menlo Security. “VMware SD-WAN by VeloCloud combined with the Menlo Security Cloud Platform powered by isolation redefines security and provides the industry’s most secure solution for Internet and SaaS applications.”
"VMware SD-WAN provides the optimal combination of intrinsic security in the multi-service Edge for corporate traffic as well as SD-WAN optimized access via our Network of Clouds Service gateways to the innovative Menlo Security Cloud Platform powered by isolation," said Steve Woo, senior director of product management at VMware. "Access to cloud and SaaS applications is automatically provisioned, optimized for performance and secured with VMware SD-WAN and Menlo Security Cloud Platform."
VMware SD-WAN customers have simplified their branch office networking and optimized application performance over the Internet. Secure Cloud Transformation, powered by isolation, allows companies to improve security control and visibility across their SD-WAN deployment. Moving to SD-WAN requires an enterprise to move their security to the cloud since user traffic is not backhauled to a central security stack. Menlo Security Cloud Platform allows users to go directly to the Internet while ensuring consistent and robust security controls, whether they are connecting from HQ, remote offices, on the road or in a coffee shop.
Menlo Security’s customers include some of the largest enterprises and government agencies. The company’s cloud security platform currently processes more than 500 million web requests per day. Among the company’s customers are seven of the 10 largest banks, four of the five largest credit-card issuers and some of the largest energy and transportation companies in the world.
For more information, please send an email to ask@menlosecurity.com.
Additional Resources
- Secure Cloud Transformation
- Menlo Security Secure Web Gateway
- Definitive Guide to Internet Isolation
VMware and SD-WAN by VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
About Menlo Security
Menlo Security protects organizations from cyber attacks by eliminating the threat of malware from the web, documents and email. Its cloud-based Isolation Secure Web Gateway scales to provide comprehensive protection across enterprises of any size, without requiring endpoint software or impacting the end user-experience. The company was named a Visionary in the Gartner Magic Quadrant for the Secure Web Gateway. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC and JP Morgan Chase. Menlo Security is headquartered in Palo Alto, California. For more information, visit https://www.menlosecurity.com or ask@menlosecurity.com
VMware, and VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005218/en/
Contact information
Lexie Janney
Merritt Group for Menlo Security
703.390.1531
janney@merrittgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom